BMRN
Biomarin Pharmaceutical Inc
61.40$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -79.7% | +70.9% | +152.8% | +86.5% | -16.2% | -6.1% | +6.2% | +99.0% | -73.0% | +121.4% | -23.8% | – | |
| – | +4.6% | +1.8% | -3.2% | -28.2% | +24.2% | -6.5% | -15.9% | -0.4% | +10.6% | -19.7% | +495.0% | – | |
| – | +13.4% | +6.2% | -17.7% | -9.2% | +19.4% | -27.4% | +26.1% | +3.6% | -4.8% | -7.4% | +74.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -343.3% | – | – | – | -312.9% | – | – | – | -82.4% | +86.7% | -239.2% | – | |
| – | +56.7% | -7.1% | -36.0% | -3.0% | -4.1% | -17.4% | +2.0% | +97.4% | +20.7% | -48.6% | +37.7% | – | |
| – | +41.8% | -78.1% | – | -117.9% | – | -137.0% | -55.4% | +2,528.4% | -87.2% | – | -803.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -13.6% | +1,174.2% | -66.4% | -64.8% | -17.0% | +690.0% | – | – | +0.0% | -27.3% | – | – | |
| – | – | – | – | – | -100.0% | – | – | – | – | – | +229.4% | – | |
| – | – | -494.8% | – | -4,057.5% | – | -1,456.4% | -88.1% | -52.9% | – | +25,657.6% | +236.8% | – | |
| – | -133.3% | – | – | -231.8% | – | -60.4% | +55.7% | -78.0% | +69.7% | +2,759.7% | -224.9% | – | |
| – | -108.2% | – | +653.3% | +106.7% | -17.5% | -4.7% | +6.7% | +99.2% | -82.4% | +239.0% | -30.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.